Telli, ML, Ford, JM (2010) PARP inhibitors in breast cancer. Clin Adv Hematol Oncol 8: pp. 629-635Telli ML, Ford JM. PARP inhibitors in breast cancer. Clin Adv Hematol Oncol. 2010;8:629-635.Telli ML, Ford JM. PARP inhibitors in breast cancer . Clin Adv Hematol Oncol (2010) 8...
The breast cancer section is a comprehensive resource for pharmacy news and expert insights. Read more at PharmacyTimes.
PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 2015; 13(1):188.Livraghi L, Garber JE, Gonzalez-Angulo A, Timms K, Liu S, Chen H, et al. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. ...
“Everyone was depressed after the phase 3 iniparib trial, but within a very short period of time, there was a resurrection of interest,” says Alan D'Andrea, a basic researcher at Dana-Farber Cancer Institute in Boston who focuses on DNA repair. “I actually think the irony of all of t...
tated Breast Cancer The Promise of PARP Inhibitors for BRCA-Mutated Breast CancerThe Promise of PARP Inhibitors for BRCA-Mutated Breast CancerTony Hagen
These therapeutics abduct the growth and multiplication of cancerous cells by disrupting certain proteins or DNA. Targeted therapies remain at the forefront, dominating over 77% of the therapy segment as of 2023. Drugs like HER2 inhibitors (e.g., trastuzumab) and CDK4/6 inhibitors are highly ...
Treatment of triple negative breast cancer (TNBC): current options and future perspectives Triple negativeBasal-likePARP inhibitorsEGFR inhibitorsAntiangiogenicsBreast cancer is not considered anymore a unique disease. Microarray gene expression analysis... MD Laurentiis,D Cianniello,R Caputo,... - 《...
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer Qingyun Zhu , Qiuzi Dai & Yuyang Jiang Article 20 December 2023 | Open Access p140Cap modulates the mevalonate pathway decreasing cell migration and enhancing drug sensit...
These developments are very promising and suggest that major advances in the targeted treatment of patients with triple-negative breast cancer are in sight... TJM Ford - 《Clinical Breast Cancer》 被引量: 133发表: 2010年 PARP inhibitors in breast cancer. The therapeutic implications of DNA damage...
Using high-dimensional single-cell profiling of human TNBC, here we demonstrate that macrophages are the predominant infiltrating immune cell type in breast cancer susceptibility (BRCA)-associated TNBC. Through multi-omics profiling, we show that PARP inhibitors enhance both anti- and pro-tumor ...